title: Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance.
abstract: Tigecycline is the first clinically available semisynthetic glycylcycline approved for clinical use. This study was done to establish a baseline for ongoing surveillance of tigecycline's activity as this agent's clinical use increases. Against 1,796 Staphylococcus aureus (559 multidrug resistant), tigecycline had the lowest minimal inhibitory concentration (MIC(90); 0.12 microg/ml) among all agents tested and 99.8% of the isolates were susceptible. For Acinetobacter spp., tigecycline again demonstrated the lowest MIC(90) (2 microg/ml) and the highest percent susceptibility (96.9%). Among Enterobacteriaceae, the 2 most active agents were tigecycline (MIC(90) = 1 microg/ml; 99% susceptible) and imipenem (MIC(90) = 1 microg/ml; 99.5% susceptible). Tigecycline also demonstrated high activity against Streptococcus pneumoniae, Streptococcus pyogenes,Haemophilus influenzae and Enterococcus spp. In summary, tigecycline currently exhibits potent activity against a broad array of bacteria species. Given the dynamics of resistance development, careful monitoring of tigecycline activity against these organisms should remain a significant aspect of ongoing surveillance.
authors.affiliation: Eurofins Medinet, Inc., Herndon, VA 20171, USA.
authors.forename: Deborah C
authors.initials: DC
authors.lastname: Draghi
authors.forename: Stacy
authors.initials: S
authors.lastname: Tench
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Dowzicky
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Sahm
mesh_terms: D000150:Acinetobacter / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects* / Q000502:physiology*; D004755:Enterobacteriaceae / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology; D000078304:Tigecycline
chemical_list: D000078304:Tigecycline; D008911:Minocycline